IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models.
暂无分享,去创建一个
S. Mustjoki | T. Fioretos | K. Porkka | J. Richter | C. Karlsson | H. Lilljebjörn | H. Wadenvik | M. Askmyr | M. Rissler | H. Ågerstam | N. Hansen | S. von Palffy | N. Landberg | C. Högberg | M. Järås | C. Sandén | K. Reckzeh
[1] T. Holyoake,et al. Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. , 2016, Blood.
[2] T. Fioretos,et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia , 2015, Proceedings of the National Academy of Sciences.
[3] D. Tenen,et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. , 2015, Cancer cell.
[4] T. Holyoake,et al. Do we need more drugs for chronic myeloid leukemia? , 2015, Immunological reviews.
[5] R. Larson,et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. , 2014, Cancer cell.
[6] G. Stefanzl,et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. , 2014, Blood.
[7] T. Suda,et al. The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. , 2014, Blood.
[8] E. Nievergall,et al. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. , 2014, Blood.
[9] J. Cayuela,et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Melo,et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. , 2013, Blood.
[11] Alex S. Arvanitakis,et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. , 2013, Blood.
[12] S. Flamant,et al. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. , 2013, Cancer research.
[13] S. Mustjoki,et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy , 2013, Leukemia.
[14] S. Ben-Neriah,et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. , 2012, Blood.
[15] Jos W. M. van der Meer,et al. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.
[16] R. Hehlmann. How I treat CML blast crisis. , 2012, Blood.
[17] T. Holyoake,et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. , 2012, Cancer cell.
[18] J. Wolchok,et al. Antibody therapy of cancer , 2012, Nature Reviews Cancer.
[19] A. Hamilton,et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. , 2012, Blood.
[20] M. Hino,et al. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib , 2012, Leukemia & lymphoma.
[21] R. Bhatia,et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. , 2011, Blood.
[22] B. Druker,et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.
[23] S. Mustjoki,et al. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy , 2010, European journal of haematology.
[24] C. Lassen,et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein , 2010, Proceedings of the National Academy of Sciences.
[25] Thomas Kamradt,et al. The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. , 2010, Blood.
[26] T. Naoe,et al. Irrespective of CD34 expression, lineage‐committed cell fraction reconstitutes and re‐establishes transformed Philadelphia chromosome‐positive leukemia in NOD / SCID / IL‐2Rγc−/− mice , 2010, Cancer science.
[27] Axel Weber,et al. Interleukin-1 (IL-1) Pathway , 2010, Science Signaling.
[28] C. Dinarello,et al. Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.
[29] C. Cahill,et al. Interleukin (IL) 1β Induction of IL-6 Is Mediated by a Novel Phosphatidylinositol 3-Kinase-dependent AKT/IκB Kinase α Pathway Targeting Activator Protein-1* , 2008, Journal of Biological Chemistry.
[30] M. Deininger,et al. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. , 2007, Blood.
[31] P. Valent,et al. Detection of molecular targets on the surface of CD34+/CD38− stem cells in various myeloid malignancies , 2006, Leukemia & lymphoma.
[32] C. Eaves,et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease , 2005, Leukemia.
[33] R. Ren,et al. Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.
[34] Laurie E Ailles,et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.
[35] K. McIntyre,et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. , 1998, Journal of immunology.
[36] I. Lewis,et al. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. , 1998, Blood.
[37] Z. Estrov,et al. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity , 1991 .
[38] J. Rowley. A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.
[39] S. Mustjoki,et al. IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome , 2016, Leukemia.